It has been also demonstrated [34] that prostate tumor cells with increased levels of SRD5A2 expression exhibit significantly reduced matrix metallopeptidase 2 (MMT2) activity compared to control cells. This evidence concerns the gene SRD5A2 and prostate neoplasm.